Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
CAH Is Entering a New Era: Commercial Execution Will Determine the Winner
A clinical, scientific, and commercial review of current CAH therapy, emerging ACTH receptor antagonism, and the market factors likely to determine the next generation of care.
Read articleCushing's Syndrome and Cushing Disease: Treatment Value Begins with the Correct Diagnosis
For Cushing's syndrome, commercial success depends less on competition than on identifying patients early enough to enter the treatment pathway—diagnosis is the first commercial barrier.
Read articleWhy Rare Disease Commercial Forecasts Often Miss Reality
Optimistic rare disease forecasts often overlook commercial friction—diagnosis delays, Centers of Excellence access, reimbursement, and adoption—that shrink the treatable population before launch.
Read articleThe Future of Hiring in Biotechnology
Why great resumes don't always build great organizations—and why collaboration, trust, and organizational fit now matter as much as experience.
Read articleWill Gene Therapy Cure Epilepsy?
Why correcting the gene may not be enough—once abnormal brain networks have formed, gene therapy success depends on more than restoring a protein.
Read articleChoosing the Right Commercial Direction in Biotechnology
Why strategic decisions made years before approval shape long-term success—Advance the Asset, Prepare for Commercial Success, or Build an Enduring Company.
Read articleSuccessful Product Commercialization in Adult and Pediatric Neurology
Building scientific partnerships that drive clinical adoption—why commercialization in neurology begins years before approval, not at launch.
Read articleWhy Gene Therapy Is Fundamentally Different from Every Other Pharmaceutical Launch
Traditional launches scale through physician adoption and recurring prescriptions. Gene therapy succeeds by finding the right patients, preparing specialized centers, and executing flawlessly for every eligible patient.
Read article